A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: Comparison to reported values and inconsistencies found in literature

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 153-164

  DeMoor, Patricia A ^a   Matusov, Yuri ^a   Kelly, Colleen ^a   Kolan, Shobha ^a   Barnachea, Linda ^a   Bazhenova, Lyudmila A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Hypersensitivity reactions; Immunotherapeutics; Literature review

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPOTHILONE A; ETOPOSIDE; GEMCITABINE; GEMTUZUMAB; IMMUNOGLOBULIN; INFLIXIMAB; INTERFERON; IRINOTECAN; IRON DERIVATIVE; LIDOCAINE; OFATUMUMAB; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROCHLORPERAZINE; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; VANCOMYCIN;

ACUTE HYPERSENSITIVITY REACTION; ADVERSE OUTCOME; ARTICLE; BLOOD; CANCER CENTER; CANCER GRADING; CLINICAL PRACTICE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; ELECTRONIC MEDICAL RECORD; ERYTHROCYTE CONCENTRATE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; PHARMACY; RETROSPECTIVE STUDY; THROMBOCYTE;

EID: 84863608169     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.153     Document Type: Article

References (103)

1. Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18: 102-5.
2. Colwell HH, Mathias SD, Ngo NH, et al. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives. J Infus Nurs 2007; 30: 153-60.
3. Bonosky K, Miller R. Hypersensitivity reactions to oxaliplatin: what nurses need to know. Clin J Oncol Nurs 2005; 9: 325-30.
4. Escalante CP, Oh JH, Baum DD, et al: Immediate adverse reactions to chemotherapy: Experience of a large ambulatory treatment center. ASCO Annual Meeting. J Clin Oncol 2006;: 8558.
5. Genentech Inc. Rituxan (rituximab) [package insert]. South San Francisco, California: Genentech Inc. 2008.
6. Plosker GL, Figgitt DP. Rituximab: a review of its use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leu-kaemia. Drugs 2003; 63: 803.
7. Onrust SV, Lamb HM, Barman Balfour JA. Rituximab. Drugs 1999; 58: 79-88.
8. Sehn LH, Donaldson J et al. Rapid infusion rituximab in combination with steroid-containing chemotherapy can be given safely and substantially reduces resource utilization. Blood 2004; 104: 1407.
9. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992; 19: 458-77.
10. Feldweg AM, Lee CW, Matulonis UA, et al. Rapid desensitiza-tion for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005; 96: 824-9.
11. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8.
12. Olson JK, Sood AK, Sorosky JI, et al. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol 1998; 68: 25-8.
13. Lenz HJ. Management and preparedness for infusion and hy-persensitivity reactions. Oncologist 2007; 12: 601-9.
14. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001; 24: 767-79.
15. Myers JS. Paclitaxel-related hypersensitivity reactions and monitoring recommendations. Clin J Oncol Nurs 2002; 6: 177-8.
16. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004-14.
17. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24: 253-62.
18. Teva Pharmaceuticals. Paclitaxel injection [package insert]. Irvine, California: Teva Pharmaceuticals; 2008.
19. Saunders MP, Denton CP, O'Brien ME, et al. Hypersensitivity reactions to cisplatin and carboplatin--a report on six cases. Ann Oncol 1992; 3: 574-6.
20. Weidmann B, Mulleneisen N, Bojko P, et al. Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and man-agement. Cancer 1994; 73: 2218-22.
21. Teva Parenteral Medicines. Carboplatin injection [package insert]. Irvine, California: Teva Parenteral Medicines; 2007.
22. Hendrick AM, Simmons D, Cantwell BM. Allergic reactions to carboplatin. Ann Oncol 1992; 3: 239-40.
23. Morgan JS, Adams M, Mason MD. Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 1994; 30A: 1205-6.
24. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reac-tions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001; 61:129-33.
25. Schwartz JR, Bandera C, Bradley A, et al. Does the platinum-free interval predict the incidence or severity of hyper-sensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol 2007; 105: 81-3.
26. Tonkin KS, Rubin P, Levin L. Carboplatin hypersensitivity: case reports and review of the literature. Eur J Cancer 1993; 29A: 1356-7.
27. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003; 89: 477-81.
28. Gowda A, Goel R, Berdzik J, et al. Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology 2004; 18: 1671-5.
29. Bayer Healthcare Pharmaceuticals Inc. Campath (alemtuzumab) [package insert]. Wayne, New Jersey: Bayer Healthcare Pharmaceuticals Inc. 2008.
30. Centocor Ortho Biotech Inc. Infliximab (Remicade for IV injection) [package insert]. Malvern, Pennsylvania: Centocor Ortho Biotech Inc. 2009.
31. Schaible TF: Long-term safety of infliximab. Can J Gastroenterol 2000; 14 (Suppl C): 29C-32C.
32. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993; 9:254-62.
33. Gurcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in pemphigus or pemphigoid. Ann Pharmacother 2007; 41:1604-10.
34. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133: 247-51.
35. Elligers KT, Davies M, Sanchis D, et al. Rechallenge with cis-platin in a patient with pancreatic cancer who developed a hy-persensitivity reaction to oxaliplatin. Is skin test useful in this setting? J Pancreas 2008; 9: 197-202.
36. de Lemos ML. Acute reactions to chemotherapy agents. J Oncol Pharm Pract 2006; 12: 127-9.
37. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004; 9: 546-9.
38. Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the in-troduction of a desensitization schedule. J Clin Oncol 2002; 20:1146-7.
39. Saif MW. Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf 2006; 5:687-94.
40. Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006; 17: 259-61.
41. Thomas RR, Quinn MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003; 97: 2301-7.
42. Syrigou EI, Karapanagiotou EM, Alamara CV, et al. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 2009; 8: 106-9.
43. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
44. Teva Parenteral Medicines. Oxaliplatin for injection [package insert]. Irvine, California: Teva Parenteral Medicines; 2009.
45. Gabizon AA. Pegylated Liposomal Doxorubicin:Metamorphosis of an old drug into a new form of chemotherapy. Cancer Inv 2001; 19: 424-36.
46. Chanan-Khan A, Szebeni J, Saway S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions. Ann Oncol 2003; 14: 1430-37.
47. Skubitz KM. Phase II Trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Inv 2003; 21: 167-76.
48. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102: 179-87.
49. Ardavanis A, Tryfonopoulos D, Yiotis I, et al. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004; 15: 581-5.
50. Sanofi-Aventis US. Taxotere (Docetaxel injection concentrate) [package insert]. Bridgewater, New Jersey: Sanofi-Aventis US; 2008.
51. Bernstein BJ. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. Ann Pharmacother 2000; 34: 1332-5.
52. Genentech Inc. Avastin (bevacizumab) [package insert]. South San Francisco, CA: Genentech Inc. 2007.
53. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007; 25:2691-5.
54. Genentech Inc. Herceptin (trastuzumab) [package insert]. South San Francisco, California: Genentech Inc. 2003.
55. Beeram M, Burris HA, Modi S, et al. A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conju-gate (ADC), given every 3 weeks to patients with HER2+ met-astatic breast cancer. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 29-June 3, 2008.
56. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 2010; 28:1749-55.
57. Castillo J, Milani C, Mendez-Allwood J. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 2009; 18: 491-500.
58. Anderson T, Javadpour N, Schilsky R, et al. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial. Cancer Treat Rep 1979; 63: 1687-92.
59. Baum ES, Gaynon P, Greenberg L, et al. Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report. Cancer Treat Rep 1979; 63:1621-7.
60. Blumenreich MS, Needles B, Yagoda A, et al. Intravesical cis-platin for superficial bladder tumors. Cancer 1982; 50: 863-5.
61. Cheng E, Cvitkovic E, Wittes RE, et al. Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer 1978; 42: 2162-8.
62. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414-20.
63. Koren C, Yerushalmi R, Katz A, et al. Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 2002; 25: 625-6.
64. Merrin CE. Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients. Cancer Treat Rep 1979; 63: 1579-84.
65. O'Brien ME, Souberbielle BE. Allergic reactions to cytotoxic drugs-an update. Ann Oncol 1992; 3: 605-10.
66. Rozencweig M, von Hoff DD, Slavik M, et al. Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med 1977; 86: 803-12.
67. Shlebak AA, Clark PI, Green JA. Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 1995; 35: 349-51.
68. Thigpen T, Shingleton H, Homesley H, et al. cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 1979; 63: 1549-55.
69. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979; 63: 1527-31.
70. Weiss RB. Hypersensitivity reaction to cancer chemotherapy. Semin Oncol 1982; 9: 5-13.
71. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981; 94: 66-72.
72. Planner RS, Weerasiri T, Timmins D, et al. Hypersensitivity reactions to carboplatin. J Natl Cancer Inst 1991; 83: 1763-4.
73. Wiesenfeld M, Reinders E, Corder M, et al. Successful re-treatment with cis-dichlorodiammineplatinum(II) after apparent allergic reactions. Cancer Treat Rep 1979; 63: 219-21.
74. Gottlieb JA, Drewinko B. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 1975; 59: 621-8.
75. Khan A, Hill JM, Grater W, et al. Atopic hypersensitivity to cisdichlorodiammine platinum (II) and other platinum complexes. Cancer Res 1975; 35: 2766-70.
76. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin Skin Testing: A Skin-Testing Protocol for Predicting Hypersensitivity to Carboplatin Chemotherapy. J Clin Oncol 2001; 19: 3126-9.
77. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal carcinoma. N Engl J Med 2004; 351: 337-45.
78. Waqar SN, Tan BR, Zubal B, et al. Race and albuterol premedication are risk factors for hypersensitivity reactions to cetuximab (abstract 20503). J Clin Oncol 2008; 26: a20503.
79. ImClone Systems Inc and Bristol-Myers Squibb Company. Erbitux (cetuximab) [package insert]. Branchburg and Princeton, New Jersey: ImClone Systems Inc and Bristol-Myers Squibb Company; 2004.
80. Wyeth Pharmaceuticals. Mylotarg (gemtuzumab) [package insert]. Philadelphia, Pennsylvania: Wyeth Pharmaceuticals; 2008.
81. Giles FJ, Cortes JE, Halliburton JA, et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacotherap 2003; 37: 1182-5.
82. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-54.
83. Leopold LH, Berger MS, Feingold J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma 2002; 2 (Suppl 1): S29-34.
84. Eli Lilly and Company. Alimta (pemetrexed) [package insert]. Indianapolis, Indiana: Eli Lilly and Company; 2005.
85. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
86. Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hyper-sensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993; 11: 1080-4.
87. [Internet] The Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, versions 3.0 and 4.0. http://ctep.cancer.gov/forms.
88. Cmelak AJ, Lordick F, Borner M, et al. Management of infusion reactions in clinical trials and beyond - the US and EU per-spectives. Oncology 2009; 23 (Suppl 1): 18.
89. Freedman SO, Krupey J. Respiratory allergy caused by plati-num salts. J Allergy 1968; 42: 233-237.
90. Chung CH, O'Neil BH. Infusion reactions to monoclonal anti-bodies for solid tumors: immunologic mechanisms and risk factors. Oncology 2009; 23:14-7.
91. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
92. Peereboom DM, Donehower RC, Eisenhauer EA, et al. Successful retreatment with Taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11: 885-90.
93. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993; 4: 610-1.
94. Tankanow RM. Docetaxel: a taxoid for the treatment of meta-static breast cancer. Am J Health Syst Pharm 1998; 55: 1777-91.
95. Verweij J, Catimel G, Sulkes A, et al. Phase II studies of docet-axel in the treatment of various solid tumours. Eur J Cancer 1995; 31A (Suppl 4): S21-S24.
96. Wanders J, Schrijvers D, Bruntsch U. The EORTC-ECTG experience with acute hypersensitivity reactions in Taxotere studies. Proc Am Soc Clin Oncol 1993; 12: 73.
97. Verwey J, Clavel M, Chevalier B. Paclitaxel (Taxol) and Docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994; 5: 495-505.
98. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
99. Brown AF, McKinnon D, Chu K. Emergency Department ana-phylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001; 108: 861-866.
100. Gleich GJ, Leiferman KM. Anaphylaxis: Implications of monoclonal antibody use in oncology. Oncology 2009; 23: 7-13.
101. Bailie GR, Clark JA, Lane CE. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-9.
102. Sanders RP, Geiger TL, Heddle N, et al. A revised classification scheme for acute transfusion reactions. Transfusion 2007; 47: 621-8.
103. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13: 725-32.